cochlear presentation

7/30/2019 Cochlear Presentation

1/9

Cochlear Limited History

http://www.cochlear.com/files/assets/timeline.swf
http://www.cochlear.com/files/assets/timeline.swfhttp://www.cochlear.com/files/assets/timeline.swfhttp://www.cochlear.com/files/assets/timeline.swfhttp://www.cochlear.com/files/assets/timeline.swfhttp://www.cochlear.com/files/assets/timeline.swf


2/9

Cochlear Limited first mover benefit

Cochlear was first to receive: US Food and Drug Administration approval for cochlear implants for

adults US Food and Drug Administration approval for cochlear implants in

children Approval for use in Japan Undertake Auditory Brainstem Implant Surgery Offer a multi-channel BTE speech processor Develop a non-invasive test of neural response at up to 22 separate

sites within the cochlear US Food and Drug Administration approval for infants at 12 months Develop an implant with a self-curling, 22 channel perimodiolar

electrode array


3/9

Strategic capabilities

Sources: company annual reports, investor reports

Major Company Economics Skills, Products & Expertise Organizational services, Strategic locations & HumanResource

Cochlear limited

Market Share: 65%

EBITDA Margin: 30.73 %

Sales:23087 Units (2012)

Total Revenue: $779.0 m(2012)

R&D Investment: $119.3m(15.3% of ttl revenue)

Skills & Culture: R&D, Innovation, Brandrecognition, onsite manufacturing benefit,work diversity with 60+ ethnic groups onlyin Sydney office. 35% of senior executivesand 48% of employees are females.

Products: The Cochlear Nucleus range of cochlear implant systems, the CochlearBaha range of bone conduction systemsand the Cochlear Hybrid electro-acoustichearing solution.

Expertise: Cochlear academy, Green fever,green house gas emissions, 950+registered patents, Nucleus CI422 cochlearimplant with Slim Straight electrode, thethinnest full length electrode on themarket, community support programme.

Offices: Headquarters are based in Sydney,Australia, and offices in Melbourne, Hong Kong,Beijing, Belgium, Tokyo, Basel, Hanover andDenver

Number of employees: 2500+ employees in 25

countries in which 500 qualified engineers.

Manufacturing: Two products in Australia, one inSweden

Services: Life time care and support for Cochlearservices

Staff: 350 specialised R& D scientists (Australia,Sweden, Belgium & USA)

Collaboration: 100 External research partners in20 Countries

Quality: World wide QA system which complieswith all regulatory requirements.


4/9

Cochlear Limited Competitive Advantage

Global market leader in implantable hearing technology. Has a reputation of delivering the most reliable and safest

implantable devices, despite voluntarily recalling one of their ownproducts in September 2011.

Maintains strong brand awareness with healthcare professionalsand hearing specialists.

Invest about 13% of revenue each year on technological innovationin order to stay ahead of the competition.

Enjoys a strong international distribution base for their products. Building the business to handle more growth by investing in

marketing and sales resources. Reports significant unmet clinical need for their products due to

growth from emerging markets.


5/9

Cochlear Limited Strategy Analysis

Strategy is to maintain its market position as the clear leader inimplantable hearing technology.

COH has a reputation of delivering the most reliable and safestimplantable device provides strong brand awareness with hearingspecialists.

To build on this credibility and its international distribution base todevelop product awareness about the Baha device to the larger hearingimpaired market.

Less than 10% of the profoundly deaf have an implantable hearing device,management expect they can exploit the immaturity of the global market.

COH is investing in research to redesign devices to enable manufacturingscale-up from a cottage industry to a production line.

Management is also building the infrastructure to handle more revenue byinvesting in marketing and sales resources.


6/9


Cochlear reported NPAT of $77.67m for the half-year ended 31December 2012. Revenues from ordinary activities were $391.7m,up 1% from the same period last year. Sales, excluding FX contracts,were $368.2m, up 5%. In constant currency (that is restating H1 F12

at H1 F13 FX rates), H1 F13 sales were up 9%. Diluted EPS was 136.1cents compared to (35.8) cents last year. Net operating cash flowwas $28.52m compared to $67.37m last year. The interim dividenddeclared was 125 cents compared with 120 cents last year. Net debtwas $72.5m at 31 December 2012. At 31 December, the unused

portion of the facility was $60.3m (June 2012, $128.0m).Year to Jun NPAT EPS EPS chg (%) PER DPS Yield (%) Franking

(%) 2014 183.9 314.9 20.6 20.8 249.0 3.8 50.02013 152.4 261.0 -6.4 25.1 215.0 3.3 50.02012 158.1 278.9 -11.7 22.0 245.0 4.0 18.0


7/9



8/9

STEEPLE/PESTEL

Competition,Threat of newcompetition,

Pricecompetitiveness,

change in

consumer taste,economicfactors


9/9

http://www.cochlear.com/files/investors/AnnualReport2008/ed17_rdo.htm http://wps.pearsoned.co.uk/ema_uk_he_johnson_excorpstrat_7/26/6677/17094

03.cw/index.html http://www.cochlear.com/files/assets/timeline.swf http://www.emeraldinsight.com.simsrad.net.ocs.mq.edu.au/search.htm?ct=all&s

t1=Strategic+capabilities+which+lead+to+management+consulting+success+in+Australia&fd1=all&mm1=all&bl2=and&st2=&fd2=all&mm2=all&bl3=and&st3=&fd3=all&mm3=all&ys=all&ye=all&ec=0&ec=1&bf=0&bf=1&search=Search&cd=ac

http://www.docstoc.com/docs/54867818/Cochlear-Limited-%28COH%29---Financial-and-Strategic-SWOT-Analysis-Review

http://www.cochlear.com/wps/wcm/connect/intl/about/investor/annual-reports
http://www.cochlear.com/files/investors/AnnualReport2008/ed17_rdo.htmhttp://wps.pearsoned.co.uk/ema_uk_he_johnson_excorpstrat_7/26/6677/1709403.cw/index.htmlhttp://wps.pearsoned.co.uk/ema_uk_he_johnson_excorpstrat_7/26/6677/1709403.cw/index.htmlhttp://www.cochlear.com/files/assets/timeline.swfhttp://www.docstoc.com/docs/54867818/Cochlear-Limited-(COH)---Financial-and-Strategic-SWOT-Analysis-Reviewhttp://www.docstoc.com/docs/54867818/Cochlear-Limited-(COH)---Financial-and-Strategic-SWOT-Analysis-Reviewhttp://www.cochlear.com/wps/wcm/connect/intl/about/investor/annual-reportshttp://www.cochlear.com/wps/wcm/connect/intl/about/investor/annual-reportshttp://www.cochlear.com/wps/wcm/connect/intl/about/investor/annual-reportshttp://www.cochlear.com/wps/wcm/connect/intl/about/investor/annual-reportshttp://www.cochlear.com/wps/wcm/connect/intl/about/investor/annual-reportshttp://www.docstoc.com/docs/54867818/Cochlear-Limited-(COH)---Financial-and-Strategic-SWOT-Analysis-Reviewhttp://www.docstoc.com/docs/54867818/Cochlear-Limited-(COH)---Financial-and-Strategic-SWOT-Analysis-Reviewhttp://www.docstoc.com/docs/54867818/Cochlear-Limited-(COH)---Financial-and-Strategic-SWOT-Analysis-Reviewhttp://www.docstoc.com/docs/54867818/Cochlear-Limited-(COH)---Financial-and-Strategic-SWOT-Analysis-Reviewhttp://www.docstoc.com/docs/54867818/Cochlear-Limited-(COH)---Financial-and-Strategic-SWOT-Analysis-Reviewhttp://www.docstoc.com/docs/54867818/Cochlear-Limited-(COH)---Financial-and-Strategic-SWOT-Analysis-Reviewhttp://www.docstoc.com/docs/54867818/Cochlear-Limited-(COH)---Financial-and-Strategic-SWOT-Analysis-Reviewhttp://www.docstoc.com/docs/54867818/Cochlear-Limited-(COH)---Financial-and-Strategic-SWOT-Analysis-Reviewhttp://www.docstoc.com/docs/54867818/Cochlear-Limited-(COH)---Financial-and-Strategic-SWOT-Analysis-Reviewhttp://www.docstoc.com/docs/54867818/Cochlear-Limited-(COH)---Financial-and-Strategic-SWOT-Analysis-Reviewhttp://www.docstoc.com/docs/54867818/Cochlear-Limited-(COH)---Financial-and-Strategic-SWOT-Analysis-Reviewhttp://www.docstoc.com/docs/54867818/Cochlear-Limited-(COH)---Financial-and-Strategic-SWOT-Analysis-Reviewhttp://www.docstoc.com/docs/54867818/Cochlear-Limited-(COH)---Financial-and-Strategic-SWOT-Analysis-Reviewhttp://www.docstoc.com/docs/54867818/Cochlear-Limited-(COH)---Financial-and-Strategic-SWOT-Analysis-Reviewhttp://www.docstoc.com/docs/54867818/Cochlear-Limited-(COH)---Financial-and-Strategic-SWOT-Analysis-Reviewhttp://www.docstoc.com/docs/54867818/Cochlear-Limited-(COH)---Financial-and-Strategic-SWOT-Analysis-Reviewhttp://www.docstoc.com/docs/54867818/Cochlear-Limited-(COH)---Financial-and-Strategic-SWOT-Analysis-Reviewhttp://www.cochlear.com/files/assets/timeline.swfhttp://www.cochlear.com/files/assets/timeline.swfhttp://wps.pearsoned.co.uk/ema_uk_he_johnson_excorpstrat_7/26/6677/1709403.cw/index.htmlhttp://wps.pearsoned.co.uk/ema_uk_he_johnson_excorpstrat_7/26/6677/1709403.cw/index.htmlhttp://wps.pearsoned.co.uk/ema_uk_he_johnson_excorpstrat_7/26/6677/1709403.cw/index.htmlhttp://www.cochlear.com/files/investors/AnnualReport2008/ed17_rdo.htmhttp://www.cochlear.com/files/investors/AnnualReport2008/ed17_rdo.htm

cochlear presentation

Documents